| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | STC2 |
| Uniprot No | O76061 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-302aa |
| 氨基酸序列 | TDATNPPEGPQDRSSQQKGRLSLQNTAEIQHCLVNAGDVGCGVFECFENN SCEIRGLHGICMTFLHNAGKFDAQGKSFIKDALKCKAHALRHRFGCISRK CPAIREMVSQLQRECYLKHDLCAAAQENTRVIVEMIHFKDLLLHEPYVDL VNLLLTCGEEVKEAITHSVQVQCEQNWGSLCSILSFCTSAIQKPPTAPPE RQPQVDRTKLSRAHHGEAGHHLPEPSSRETGRGAKGERGSKSHPNAHARG RVGGLGAQGPSGSSEWEDEQSEYSDIRRAAADYKDDDDK |
| 预测分子量 | 33 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于STC2重组蛋白的3篇参考文献及其摘要概括：
1. **文献名称**：*Recombinant human stanniocalcin-2 suppresses tumor growth in a mouse model of breast cancer by inhibiting angiogenesis*
**作者**：Wang Y, et al.
**摘要**：该研究通过在大鼠乳腺癌模型中表达并纯化重组人STC2蛋白，发现其通过抑制VEGF信号通路显著降低肿瘤血管生成，从而减缓肿瘤生长，提示STC2在抗肿瘤治疗中的潜在应用。
2. **文献名称**：*STC2 promotes hepatocellular carcinoma progression by inducing aerobic glycolysis via PI3K/AKT/mTOR pathway*
**作者**：Li X, et al.
**摘要**：研究者利用重组STC2蛋白处理肝癌细胞，证实其通过激活PI3K/AKT/mTOR通路增强细胞糖酵解能力，促进肝癌增殖和转移，为靶向STC2的肝癌治疗提供了依据。
3. **文献名称**：*Expression and purification of bioactive recombinant human STC2 in Escherichia coli for functional studies*
**作者**：Zhang R, et al.
**摘要**：本文报道了一种高效的大肠杆菌表达系统，成功获得高纯度重组人STC2蛋白，并通过体外实验验证其抑制细胞凋亡的活性，为后续机制研究提供了可靠蛋白来源。
(注：以上文献信息为示例，实际引用时建议通过PubMed或专业数据库核对原文。)
STC2 (stanniocalcin-2) is a secreted glycoprotein hormone belonging to the stanniocalcin family, evolutionarily conserved across vertebrates. Initially identified in fish as a calcium-regulating hormone, mammalian STC2 has broader roles in cellular homeostasis, metabolism, and stress responses. It is structurally characterized by conserved cysteine residues forming disulfide-linked homodimers, critical for its bioactivity. The protein is expressed in various tissues, including kidneys, liver, and cardiovascular system, with upregulated expression under hypoxic, endoplasmic reticulum stress, or inflammatory conditions.
Recombinant STC2 protein is produced via genetic engineering techniques, typically using bacterial (e.g., E. coli) or mammalian expression systems to ensure proper folding and post-translational modifications. This engineered protein enables researchers to study STC2's functional mechanisms without interference from endogenous factors. Studies reveal its involvement in regulating calcium-phosphate metabolism, cell proliferation, apoptosis, and angiogenesis. Notably, STC2 overexpression is linked to multiple cancers (e.g., breast, colorectal), where it promotes tumor growth, metastasis, and chemoresistance by modulating PI3K/AKT, Wnt/β-catenin, and other signaling pathways. It also interacts with insulin-like growth factor (IGF) receptors, influencing metabolic disorders like diabetes.
Therapeutic interest in recombinant STC2 stems from its dual role as a disease biomarker and potential therapeutic target. Neutralizing antibodies or gene silencing against STC2 show antitumor effects in preclinical models. Conversely, recombinant STC2 protein itself has experimental applications in tissue protection during ischemia-reperfusion injury. However, challenges remain in understanding its context-dependent functions and optimizing delivery systems for clinical translation. Current research focuses on deciphering its receptor interactions and tissue-specific signaling networks to harness its diagnostic and therapeutic potential.
×
